SK Biopharmaceuticals

326030.KO

54.09 USD

-2.69

-4.74%

Overview

Last close

54.09 usd

Market cap

4.24B usd

52 week high

95.49 usd

52 week low

50.09 usd

Target price

97.1 usd

Valuation

P/E

N/A

Forward P/E

81.3008

Price/Sales

6.6781

Price/Book Value

5.8174

Enterprise Value

4.17B usd

EV/Revenue

6.5142

EV/EBITDA

18.0592

Key financials

Revenue TTM

640.91M usd

Gross Profit TTM

602.33M usd

EBITDA TTM

237.45M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

916.79M usd

Net debt

N/A usd

About

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.